Fibroblast growth factors (FGFs) are a family of proteins with a well-established role in cell growth, tissue repair, and neuroprotection. There is a growing body of preclinical scientific evidence supporting the use of FGFs, particularly FGF-2 (basic FGF), in the treatment and support of nerve damage. Animal studies have demonstrated that FGFs can promote survival, differentiation, and regeneration of neurons following injury. For example, FGF-2 has been shown to enhance axonal growth, reduce neuronal apoptosis, and improve functional recovery in rodent models of peripheral nerve injury and spinal cord damage. Some studies suggest FGFs may also stimulate angiogenesis and modulate inflammatory responses, further aiding nerve repair.

However, while preclinical research is promising, clinical evidence in humans remains limited. Most studies to date have been conducted in laboratory or animal settings, with only a few early-phase trials exploring the safety and efficacy of FGFs in conditions such as spinal cord injury or peripheral neuropathy. As such, the overall evidence supporting FGF use for nerve damage is moderate and largely experimental, justifying a rating of 3 out of 5. Further clinical trials are needed to establish efficacy, optimal dosing, and safety in humans. Nonetheless, the scientific rationale and preclinical results provide a credible foundation for ongoing research in this area.